IP Library Granted Patent US 9,175,067
Granted Patent B2
US 9,175,067 · App. 13/583,686 · Granted Nov 3, 2015

Immunoglobulin G Fc region binding polypeptide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,175,067
App. No.
13/583,686
Granted
Nov 3, 2015
Kind
B2
Abstract

An immunoglobulin G Fc region binding polypeptide is provided, consisting of an amino acid sequence selected from i) a variant of Protein A domain or Protein Z and ii) an amino acid sequence which has at least 95% identity thereto. Also provided are methods for producing the polypeptide, compositions comprising the polypeptide, polynucleotides encoding the polypeptide, multimers of the polypeptide, and methods of using the polypeptide.

Claims (41)

1. An immunoglobulin G Fc region binding polypeptide, comprising an mamino acid sequence:

i) X 1 -([spacer1]-(SEQ ID NO: 10)-X 17 LPX 20 -

(SEQ ID NO: 11)-X 36 -(SEQ ID NO: 12)-

X 51 -(SEQ ID NO: 13)-[spacer2]) n -C CTERM-1 X CTERM

wherein, independently of each other,

X 1 is P or nothing;

[spacer1] is an amino acid sequence consisting of 1-3 amino acid residues;

X 17 is any amino acid residue;

X 20 is any amino acid residue;

X 36 is any amino acid residue except for D;

X 51 is any amino acid residue;

[spacer2] is an amino acid sequence consisting of 0-20 amino acid residues;

X CTERM is D or nothing;

and n is 1-4.

2. The IgG Fc-binding polypeptide of claim 1 , wherein [spacer1] is selected from A, AE and AEA.

3. The IgG Fc-binding polypeptide of claim 2 , wherein [spacer1] is A.

4. The IgG Fc-binding polypeptide of claim 1 , wherein X 17 is H.

5. The IgG Fc-binding polypeptide of claim 1 , wherein X 20 is any amino acid residue except for N, for example T.

6. The IgG Fc-binding polypeptide of claim 1 , wherein X 20 is N.

7. The IgG Fc-binding polypeptide of claim 1 , wherein X 36 is selected from E and A.

8. The IgG Fc-binding polypeptide of claim 1 , wherein X 51 is any amino acid residue except for N.

9. The IgG Fc-binding polypeptide of claim 1 , wherein X 51 is N.

10. The IgG Fc-binding polypeptide of claim 1 , wherein all amino acid residues of [spacer2] are independently selected from A, E, F, G, I, K, L, P, Q, R, S, T and V.

11. The IgG Fc-binding polypeptide of claim 1 , wherein [spacer2] is G.

12. The IgG Fc-binding polypeptide of claim 1 , wherein n is 1.

13. The IgG Fc-binding polypeptide of claim 1 , wherein n is 2.

14. The IgG Fc-binding polypeptide of claim 1 , wherein n is 4.

15. The IgG Fc-binding polypeptide of claim 1 , which binds to IgG Fc such that the K D value of the interaction is at most 1×10 −6 M.

16. The IgG Fc-binding polypeptide of claim 15 , which binds to IgG Fc such that the K D value of the interaction is at most 1×10 −7 M.

17. The IgG Fc-binding polypeptide of claim 16 , which binds to IgG Fc such that the K D value of the interaction is at most 5×10 −8 M.

18. The IgG Fc-binding polypeptide of claim 1 , which is capable of binding to the Fc portion of a human IgG molecule.

19. The IgG Fc-binding polypeptide of claim 18 , which is capable of binding to classes 1, 2 and 4 of human IgG.

20. The IgG Fc-binding polypeptide of claim 1 , which is capable of binding to the interface between the CH2 and CH3 domains of IgG Fc.

21. The IgG Fc-binding polypeptide an amino acid sequence selected from SEQ ID NO:5-6.

22. The IgG Fc-binding polypeptide of claim 1 , in which X 1 is P and X CTERM is D.

23. An IgG Fc-binding polypeptide comprising an amino acid sequence selected from SEQ ID NO:1-4.

24. A polynucleotide comprising a nucleotide sequence encoding the polypeptide of claim 1 .

25. A multimer polypeptide comprising:

at least two subunits, each subunit being the polypeptide of claim 22 ; and

an N-terminal leader peptide comprising a D residue as the last residue thereof.

26. A polynucleotide comprising the nucleotide sequence encoding a multimer polypeptide of claim 25 .

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2012
From: ABRAHMSEN, LARS
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 029113/0158 →